Thursday 19 August 2021

CAT grants collective proceedings order application in MasterCard competition law collective proceedings claim

 


 

The Competition Appeal Tribunal (CAT) has given its judgment on the remitted collective proceedings order (CPO) application by Mr Walter Hugh Merricks CBE (Merricks).  This is a milestone judgment certifying the first collective damages action for breach of competition law under the UK’s bespoke collective actions regime.

Merricks sought permission to act as the class representative to bring opt-out collective proceedings under section 47B of the Competition Act 1998 (Competition Act).  The collective proceedings concern follow-on actions for damages arising from the European Commission's 2007 decision finding that MasterCard's EEA multilateral interchange fees breached Article 101(1) TFEU.

The CAT dismissed Merricks’ application for a CPO in July 2017. The Court of Appeal and Supreme Court upheld Merricks' appeal.  The Supreme Court remitted the CPO application to the CAT for reconsideration.

The CAT authorised Merricks as the class representative under section 47B(8) of the Competition Act provided that a suitable undertaking as to liability for adverse costs is given by his litigation funder.

The CAT ruled that the claim for compound interest could not be fairly resolved in collective proceedings.  It considered that compound interest would result in a claim for a “gargantuan amount”.  The CAT expects a plausible methodology to be put forward at this stage, “even if it may need refinement later”.

The CAT also ruled that a claim for damages cannot be brought in the name of a deceased person under section 47B of the Competition Act.  The CAT held that a claim by an individual for loss caused by Mastercard's infringement of competition law will, on their death, vest in their estate.  

The CAT will hear further submissions from the parties as to the domicile date and date for opt-in and opt-out notifications to be set out in the CPO.

Walter Hugh Merricks CBE v Mastercard Incorporated and others [2021] CAT 28

Friday 6 August 2021

CMA sends statement of objections to Pfizer-Flynn – again

 

CMA sends statement of objections to Pfizer-Flynn – again

 

The Competition and Markets Authority (CMA) has issued a statement of objections in the remittal case concerning abuse of dominance by Pfizer and Flynn for charging unfair prices for phenytoin sodium capsules in the UK.

The Competition Appeal Tribunal held in June 2018 that the CMA had made errors in its conclusions on abuse of dominance and application of the legal test for excessive pricing.  The CAT remitted the case to the CMA insofar as it deals with excessive pricing.

In March 2020 the Court of Appeal dismissed an appeal by Flynn but allowed the CMA’s appeal in part as to excessive pricing.  This did not affect the CAT’s overall conclusions on excessive pricing and the Court affirmed the CAT’s decision on remittal.

The CMA has now issued a statement of objections provisionally finding that the parties abused their respective dominant positions.

For a four year period Pfizer's prices were between 780% and 1,600% higher than it had previously charged.

Pfizer supplied the drug to Flynn, which sold it to wholesalers and pharmacies at prices between 2,300% and 2,600% higher than those they had paid previously.

The statement of objections comes one week after the CMA fined Advanz Pharma in excess of £100 million for excessive pricing of the thyroid medication liothyronine.  The wording in the two press releases is very similar and suggests very similar theories of harm. 

https://www.gov.uk/government/news/cma-accuses-pharma-firms-of-illegal-pricing